Figure 2.

The advances of cfDNA-based biomarkers for early detection and tissue-of-origin of cancer

AFP, alpha fetoprotein; AXIN1, axis inhibition protein 1; bCa, bladder cancer; BMP3, bone morphogenetic protein 3; CIN2, cervical intraepithelial neoplasia grade 2; CDO1, cysteine dioxygenase type I; CNV, copy number variation; CTNNB1, catenin beta 1; DCP, des-gamma-carboxy prothrombin; EBV, Epstein-Barr virus; HOXA7, homeobox A7; HOXA9, homeobox A9; Hgb, hemoglobin; IDH, isocitrate dehydrogenase; KRAS, Kirsten rat sarcoma virus; LRG1, leucine-rich alpha-2-glycoprotein 1; NDRG4, N-Myc downstream-regulated gene 4; RASSF1A, Ras association domain family member 1; VIM, vimentin; SNV, single nucleotide variant; SFRP2, Secreted Frizzled Related Protein 2; SOX17, SRY-Box Transcription Factor 17; SEPT9, Septin 9; TIMP1, tissue inhibitor matrix metalloproteinase 1; TAC1, tachykinin precursor 1; TERT, telomerase reverse transcriptase; VHL, Von Hippel-Lindau syndrome; ZFP42, zinc finger protein 42.